美国威尔·康奈尔医学院Yelena Y. Janjigian等研究人员完成PD-1和HER2双重阻断治疗HER2阳性胃癌的KEYNOTE-811试验。该项研究成果于2021年12月15日在线发表在《自然》杂志上。
Author: Janjigian, Yelena Y., Kawazoe, Akihito, Yaez, Patricio, Li, Ning, Lonardi, Sara, Kolesnik, Oleksii, Barajas, Olga, Bai, Yuxian, Shen, Lin, Tang, Yong, Wyrwicz, Lucjan S., Xu, Jianming, Shitara, Kohei, Qin, Shukui, Van Cutsem, Eric, Tabernero, Josep, Li, Lie, Shah, Sukrut, Bhagia, Pooja, Chung, Hyun Cheol
Issue&Volume: 2021-12-15
Abstract: Human epidermal growth factor receptor 2 (HER2, also known as ERBB2) amplification or overexpression occurs in approximately 20% of advanced gastric or gastro-oesophageal junction adenocarcinomas1,2,3. More than a decade ago, combination therapy with the anti-HER2 antibody trastuzumab and chemotherapy became the standard first-line treatment for patients with these types of tumours4. Although adding the anti-programmed death 1 (PD-1) antibody pembrolizumab to chemotherapy does not significantly improve efficacy in advanced HER2-negative gastric cancer5, there are preclinical6,7,8,9,10,11,12,13,14,15,16,17,18,19 and clinical20,21 rationales for adding pembrolizumab in HER2-positive disease. Here we describe results of the protocol-specified first interim analysis of the randomized, double-blind, placebo-controlled phase III KEYNOTE-811 study of pembrolizumab plus trastuzumab and chemotherapy for unresectable or metastatic, HER2-positive gastric or gastro-oesophageal junction adenocarcinoma22 (https://clinicaltrials.gov, NCT03615326). We show that adding pembrolizumab to trastuzumab and chemotherapy markedly reduces tumour size, induces complete responses in some participants, and significantly improves objective response rate.
DOI: 10.1038/s41586-021-04161-3
Source: https://www.nature.com/articles/s41586-021-04161-3
Nature:《自然》,创刊于1869年。隶属于施普林格·自然出版集团,最新IF:69.504
官方网址:http://www.nature.com/
投稿链接:http://www.nature.com/authors/submit_manuscript.html
本期文章:《自然》:Online/在线发表